Summit Therapeutics Inc. (SMMT) Bundle
Understanding Summit Therapeutics Inc. (SMMT) Revenue Streams
Understanding Summit Therapeutics Inc.’s Revenue Streams
As of September 30, 2024, the company reported total revenue of $0 for both the three and nine months ended periods, indicating no revenue generation during these times.
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for the company remains at 0% as there were no revenues reported for the corresponding periods.
Contribution of Different Business Segments to Overall Revenue
The company operates primarily in the sectors of oncology and anti-infectives; however, it has not yet commercialized any products, leading to a contribution of $0 from these segments to overall revenue.
Analysis of Significant Changes in Revenue Streams
There have been no significant changes in revenue streams as the company has not reported any revenue for the periods under review. The ongoing focus is predominantly on research and development activities.
Revenue and Operating Loss Summary
| Period | Revenue | Operating Expenses | Net Loss |
|---|---|---|---|
| Three Months Ended September 30, 2024 | $0 | $58.1 million | $(56.3) million |
| Three Months Ended September 30, 2023 | $0 | $20.7 million | $(21.2) million |
| Nine Months Ended September 30, 2024 | $0 | $160.5 million | $(160.1) million |
| Nine Months Ended September 30, 2023 | $0 | $574.3 million | $(578.4) million |
This table reflects the ongoing trend of zero revenue, juxtaposed with increasing operating expenses and net losses as the company advances its research and development efforts without achieving commercial sales.
A Deep Dive into Summit Therapeutics Inc. (SMMT) Profitability
A Deep Dive into Summit Therapeutics Inc.'s Profitability
Gross Profit Margin: The company reported a gross profit margin of 0% for the periods ended September 30, 2024, and September 30, 2023, as the company did not generate any revenue during these periods.
Operating Profit Margin: The operating profit margin for the three months ended September 30, 2024, was (100.3%), compared to (98.1%) for the same period in 2023. The operating loss for the three months was $58.4 million for 2024 versus $20.4 million in 2023.
Net Profit Margin: The net profit margin for the three months ended September 30, 2024, was (100.1%), while it was (98.9%) for the same period in 2023. The net loss for the three months was $56.3 million in 2024 compared to $21.2 million in 2023.
Trends in Profitability Over Time
For the nine months ended September 30, 2024, the company incurred a net loss of $160.1 million, compared to $578.4 million for the same period in 2023. The reduction in net loss indicates a trend towards improving profitability.
Below is a table summarizing the profitability metrics over the last two years:
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Gross Profit Margin | 0% | 0% | 0% | 0% |
| Operating Loss | $(58.4M) | $(20.4M) | $(160.4M) | $(573.5M) |
| Net Loss | $(56.3M) | $(21.2M) | $(160.1M) | $(578.4M) |
Comparison of Profitability Ratios with Industry Averages
The company operates in a high-risk biotechnology sector where many firms experience prolonged periods of net losses due to high research and development costs. The industry average for net profit margins typically ranges from (30%) to (50%) for pre-revenue biotech firms. In comparison, the current net profit margin of (100.1%) indicates a significant divergence from the industry average.
Analysis of Operational Efficiency
The operational efficiency of the company can be assessed through its cost management strategies. The total operating expenses for the nine months ended September 30, 2024, were $160.5 million, a decrease from $574.3 million in the same period of 2023. This decline demonstrates improved cost management despite continued investment in research and development.
Research and Development Expenses: The company spent $99.4 million on research and development for the nine months ended September 30, 2024, up from $34.7 million in 2023.
General and Administrative Expenses: These expenses totaled $46.1 million for the nine months ended September 30, 2024, compared to $18.7 million in 2023.
Below is a table summarizing the operational efficiency metrics:
| Expense Type | 9M 2024 | 9M 2023 |
|---|---|---|
| Research and Development Expenses | $99.4 million | $34.7 million |
| General and Administrative Expenses | $46.1 million | $18.7 million |
| Total Operating Expenses | $160.5 million | $574.3 million |
Debt vs. Equity: How Summit Therapeutics Inc. (SMMT) Finances Its Growth
Debt vs. Equity: How Summit Therapeutics Inc. Finances Its Growth
As of September 30, 2024, Summit Therapeutics Inc. holds a mix of long-term and short-term debt, along with equity financing, to support its operations and growth initiatives.
Overview of the Company's Debt Levels
The company reported current liabilities totaling $59.0 million and non-current liabilities of $4.2 million, leading to total liabilities of $64.9 million.
Debt-to-Equity Ratio and Comparison to Industry Standards
Summit Therapeutics has a debt-to-equity ratio of approximately 0.15, calculated by dividing total liabilities of $64.9 million by total stockholders' equity of $437.9 million. This ratio is significantly lower than the industry average of around 0.5, indicating a conservative approach to leveraging debt for growth.
Recent Debt Issuances and Credit Ratings
Recently, the company has engaged in several financing activities, including a private placement that raised approximately $235 million in September 2024. As of September 30, 2024, the company had a promissory note payable to related parties totaling $24.5 million. The effective interest rates on the company’s notes range from 8.9% to 12%.
How the Company Balances Between Debt Financing and Equity Funding
Summit Therapeutics primarily finances its operations through equity offerings, including a recent at-the-market offering that raised $44.2 million. The company also utilizes short-term investments, holding $393.1 million in U.S. treasury securities as of September 30, 2024. The balance between debt and equity funding allows the company to maintain liquidity while minimizing the dilution of existing shareholders.
| Type of Financing | Amount (in millions) |
|---|---|
| Current Liabilities | $59.0 |
| Non-Current Liabilities | $4.2 |
| Total Liabilities | $64.9 |
| Total Stockholders' Equity | $437.9 |
| Debt-to-Equity Ratio | 0.15 |
| Recent Private Placement | $235.0 |
| At-the-Market Offering | $44.2 |
| Promissory Note Payable | $24.5 |
| Short-term Investments | $393.1 |
Assessing Summit Therapeutics Inc. (SMMT) Liquidity
Assessing Summit Therapeutics Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as follows:
Current Assets: $486.9 million (includes cash, cash equivalents, and short-term investments)
Current Liabilities: $59.0 million
Current Ratio = Current Assets / Current Liabilities = $486.9 million / $59.0 million = 8.24
Quick Ratio: The quick ratio excludes inventory from current assets:
Quick Assets: $486.9 million (cash and equivalents) - $0 (no inventory reported)
Quick Ratio = Quick Assets / Current Liabilities = $486.9 million / $59.0 million = 8.24
Analysis of Working Capital Trends
Working Capital (Current Assets - Current Liabilities) as of September 30, 2024:
Working Capital = $486.9 million - $59.0 million = $427.9 million
Trend Analysis:
- Working Capital as of September 30, 2023: $79.4 million
- Working Capital Increase: $348.5 million
Cash Flow Statements Overview
Operating Cash Flow
Net cash used in operating activities for the nine months ended September 30, 2024:
Net Cash Used: $(93.4 million)
Investing Cash Flow
Net cash used in investing activities for the nine months ended September 30, 2024:
Net Cash Used: $(288.8 million)
Financing Cash Flow
Net cash provided by financing activities for the nine months ended September 30, 2024:
Net Cash Provided: $404.8 million
Potential Liquidity Concerns or Strengths
As of September 30, 2024:
- Cash and Cash Equivalents: $93.8 million
- Short-term Investments: $393.1 million
- Accumulated Deficit: $(1,153.4 million)
The total liabilities as of September 30, 2024, are $64.9 million, indicating a strong liquidity position supported by substantial cash reserves compared to liabilities.
| Financial Metric | As of September 30, 2024 |
|---|---|
| Current Assets | $486.9 million |
| Current Liabilities | $59.0 million |
| Current Ratio | 8.24 |
| Quick Ratio | 8.24 |
| Working Capital | $427.9 million |
| Net Cash Used in Operating Activities | $(93.4 million) |
| Net Cash Used in Investing Activities | $(288.8 million) |
| Net Cash Provided by Financing Activities | $404.8 million |
| Cash and Cash Equivalents | $93.8 million |
| Short-term Investments | $393.1 million |
| Accumulated Deficit | $(1,153.4 million) |
| Total Liabilities | $64.9 million |
Is Summit Therapeutics Inc. (SMMT) Overvalued or Undervalued?
Valuation Analysis
To assess whether Summit Therapeutics Inc. is overvalued or undervalued, we analyze key valuation metrics including the price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, enterprise value-to-EBITDA (EV/EBITDA) ratio, stock price trends, and analyst consensus.
Price-to-Earnings (P/E) Ratio
As of September 30, 2024, the company's net loss amounted to $160.1 million, resulting in a basic net loss per share of $0.22. Given that the company has not generated revenue, the P/E ratio is not applicable.
Price-to-Book (P/B) Ratio
The book value of equity as of September 30, 2024, stands at $437.9 million with 737,094,965 shares outstanding. This results in a book value per share of approximately $0.59. With a stock price of $0.50 as of the same date, the P/B ratio is calculated as:
P/B Ratio = Stock Price / Book Value per Share
P/B Ratio = $0.50 / $0.59 ≈ 0.85
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The company reported an operating loss of $160.4 million for the nine months ended September 30, 2024. The EV/EBITDA ratio is not applicable due to the negative EBITDA.
Stock Price Trends
Over the past 12 months, the stock price has fluctuated significantly. The stock was trading at approximately $1.00 a year ago and has since declined to around $0.50 as of September 30, 2024, reflecting a 50% decrease in value.
Dividend Yield and Payout Ratios
Summit Therapeutics does not currently pay a dividend, and thus the dividend yield is 0%. The payout ratio is also not applicable as there are no earnings to distribute.
Analyst Consensus on Stock Valuation
According to the latest analyst ratings, the consensus is a “Hold” on the stock, with analysts citing concerns over the company's ongoing losses and the need for additional capital to fund operations.
Valuation Summary Table
| Metric | Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | N/A |
| Price-to-Book (P/B) Ratio | 0.85 |
| Enterprise Value-to-EBITDA (EV/EBITDA) Ratio | N/A |
| Stock Price (as of Sept 30, 2024) | $0.50 |
| 12-Month Price Change | -50% |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
Key Risks Facing Summit Therapeutics Inc. (SMMT)
Key Risks Facing Summit Therapeutics Inc.
Overview of Internal and External Risks
Summit Therapeutics Inc. faces several internal and external risks that may impact its financial health. The competitive landscape in the biotechnology sector is intense, with numerous companies vying for market share in similar therapeutic areas. Regulatory changes can also pose significant challenges, as obtaining and maintaining marketing approvals require compliance with stringent governmental standards.
Competitive Landscape
- As of September 30, 2024, the company reported a net loss of $56.3 million for the third quarter, highlighting the competitive pressures it faces in the market.
- The biotechnology sector is characterized by rapid innovation, necessitating continuous investment in research and development. Research and development expenses increased by $22.4 million in Q3 2024 compared to Q3 2023.
Regulatory Risks
The company must navigate complex regulatory environments in various jurisdictions. The recent amendment to the License Agreement with Akeso, expanding territories, required an upfront payment of $15 million.
Market Conditions
- As of September 30, 2024, the company had an accumulated deficit of $1.153 billion.
- Cash and cash equivalents stood at $93.8 million, with short-term investments in U.S. Treasury securities totaling $393.1 million.
Operational Risks
The company has not completed the development of any drugs, which contributes to its ongoing operational risks. The net cash used in operating activities for the nine months ended September 30, 2024, was $93.4 million.
Financial Risks
Recent financing activities included gross proceeds of $235 million from a private placement. However, the need for additional capital remains critical, as the company expects to incur significant losses for the foreseeable future.
Strategic Risks
The company's strategy includes continued investment in clinical development, which may not yield the expected results. Total operating expenses for Q3 2024 were $58.1 million.
Mitigation Strategies
To mitigate these risks, the company plans to raise additional equity or debt capital. As of September 30, 2024, the company had established an at-the-market offering program with $45.8 million remaining available for sale.
| Risk Category | Description | Recent Financial Impact |
|---|---|---|
| Operational Risks | Continued investment in research and development; no completed drugs | Net cash used in operating activities: $93.4 million |
| Financial Risks | Ongoing need for capital, reliance on market conditions | Accumulated deficit: $1.153 billion |
| Regulatory Risks | Compliance with complex regulations | Upfront payment for expanded territories: $15 million |
| Market Conditions | Intense competition and innovation in biotechnology | Research and development expenses increase: $22.4 million |
Overall, the financial health of the company is closely tied to its ability to manage these risks effectively while pursuing its strategic objectives. The company continues to evaluate options for financing its operations, which is critical for sustaining its research and development efforts in the competitive biotech landscape.
Future Growth Prospects for Summit Therapeutics Inc. (SMMT)
Future Growth Prospects for Summit Therapeutics Inc. (SMMT)
Analysis of Key Growth Drivers
Summit Therapeutics Inc. is positioned to leverage several key growth drivers in the coming years. The primary drivers include:
- Product Innovations: The focus on developing ivonescimab (SMT112), an oncology drug, has led to significant investments, with a total of $520.9 million allocated for its development as of September 30, 2023.
- Market Expansions: In June 2024, the company expanded its license agreement with Akeso to include Latin America, the Middle East, and Africa, with an upfront payment of $15 million.
- Strategic Partnerships: Collaboration agreements, such as those with Eurofarma Laboratórios SA, are expected to enhance commercialization efforts.
Future Revenue Growth Projections and Earnings Estimates
Future revenue growth projections indicate a potential recovery as product candidates advance through clinical trials. Analysts estimate that once ivonescimab receives regulatory approval, it could generate annual revenues exceeding $1 billion. However, the company anticipates continued operating losses in the short term, reporting a net loss of $160.1 million for the nine months ended September 30, 2024.
Strategic Initiatives and Partnerships
Summit Therapeutics is actively pursuing various strategic initiatives to bolster growth:
- Clinical Trials: Ongoing trials for ivonescimab are expected to require additional funding, with an estimated $93.4 million used in operating activities for the nine months ending September 30, 2024.
- Equity Financing: The company has filed a shelf registration statement allowing it to raise up to $450 million through various securities.
- At-the-Market Offerings: As of September 30, 2024, approximately $45.8 million remains available under its ATM program.
Competitive Advantages
Several competitive advantages position Summit Therapeutics favorably for future growth:
- Strong Intellectual Property Portfolio: The company has made significant investments in maintaining and expanding its intellectual property related to ivonescimab.
- Experienced Management Team: The management team, including key figures like CEO Robert W. Duggan, brings extensive industry experience that enhances operational execution.
- Access to Funding: The company has received substantial funding from various sources, including government entities and non-profit organizations, which provides a financial cushion for ongoing research.
| Growth Driver | Details |
|---|---|
| Product Innovations | Investment in ivonescimab: $520.9 million |
| Market Expansion | New territories added: Latin America, Middle East, Africa, with upfront payment of $15 million |
| Revenue Projections | Potential annual revenue from ivonescimab: $1 billion+ |
| Operating Losses | Net loss for 9 months ended September 30, 2024: $160.1 million |
Summit Therapeutics Inc. (SMMT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Summit Therapeutics Inc. (SMMT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Summit Therapeutics Inc. (SMMT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Summit Therapeutics Inc. (SMMT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.